Advances of polyol pathway and diabetic retinopathy

International Journal of Ophthalmology

Volumn 9, Issue 2, 2009, Pages 335-337

  Wu, Yan ^a   Lü, Hong Bin ^a   Jiang, Ling ^a   Liao, Hong Xia ^a  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

Aldose reductase; Aldose reductase inhibitors; Diabetic retinopathy; Polyol pathway

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; GLUCOSE; IDITOL DEHYDROGENASE; POLYOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; VASCULOTROPIN;

BIOCHEMISTRY; DIABETES MELLITUS; DIABETIC RETINOPATHY; GLUCOSE METABOLISM; HISTIOCYTE; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW;

EID: 62149132145     PISSN: 16725123     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1672-5123.2009.02.040     Document Type: Review

References (24)

1. Fong DS, Aiello L, Gardner TW, et al. American diabetes association: diabetic retinopathy (Review). Diabetes Care 2003;26(1):226-229
2. Dagher Z, Park YS, Asnaghi V, et al. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 2004;53(9):2404-2411
3. Treins C, Giorgetti-peraloli S, Murdaca J, et al. Regulation of vascular endothelial growth factor expression by advanced glycation end products. Biol Chem 2001;276(47):43836-43841
4. Xu GX, Xu JB, Hu JZ. Expression of hypoxia-inducible factor-1α and vascular endothelial growth factor in the retina of diabetic rats. Int J Ophthalmol (Guoji Yanke Zazhi) 2008;8(3):487-490
5. Moore TC, Moore JE, Kaji Y, et al. The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci 2003;44(10):4457-4464
6. Reber F, Geffarch R, Kasper M, et al. Graded sensitiveness of the various retinal neuron populations on the glyoxal-mediated fomation of advance glycosylation end products and ways of protection. Graefes Arch Clin Exp Ophthalmol 2003;241(3):213-225
7. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. zenarestat study group. Neurology 1999;53(4):580-591
8. Ola MS, Berkich DA, Xu Y, et al. Analysis of glucose metabolism in diabetic rat retinas. Am J Physiol Endocrinol Metab 2006;290 (6): E1057-1067
9. Lu BY, Wu ZF. Progress of research on pathogenesis of diabetic retinopathy. Int J Ophthalmol (Guoji Yanke Zazhi) 2008;8(11):2308-2311
10. Lorenzi M, Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia 2001;44(7):791-804
11. Mylari BL, Armento SJ, Beebe DA, et al. A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners. J Med Chem 2005;48(20):6326-6339
12. Grant MB, Afzal A, Spoerri P, et al. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004;13(10):1275-1293
13. Witmer MN, Vrensen GF, Van Noorden CJ, et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22(1):1-29
14. Obrosova IG, Minchenko AG, Vasupuram R, et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 2003;52(3):864-871
15. Bril V, Buchanan RA. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2004;27(10):2369-2375
16. Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006;29(1):68-72
17. Graesser D, Solowiej A, Bruckner M, et al. Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. Clin Invest 2002;109(3):383-392
18. Asnaghi V, Gerhardinger C, Hoehn T, et al. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003;52(2):506-511
19. Engerman RL, Kern TS, Larson ME. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs. Diabetologia 1994;37(2):141-144
20. Dagher Z, Park YS, Asnaghi V, et al. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 2004;53(9):2404-2411
21. Sun W, Gerhardinger C, Dagher Z, et al. Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects. Diabetes 2005;54(12):3418-3426
22. Sun W, Oates PJ, Coutcher JB, et al. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 2006;55(10):2757-2762
23. Beltramo E, Berrone E, Buttiglieri S, et al. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev 2004;20(4):330-336
24. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9(3):294-299